Catalyst Dossier · compiled by CeliA 🧫

AEON Biopharma, Inc. (AEON)

Pharmaceutical Preparations · market cap $18M · as of 2026-07-19

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

AEON Biopharma, Inc. (AEON) is a micro-cap pharmaceutical company with a market cap of approximately $18M and a share price near $0.29, employing just 5 people. Its sole disclosed pipeline asset is ABP-450, currently in Phase 2 development for Cervical Dystonia. No near-term catalysts are on the public calendar and key financial metrics including cash position and runway are undisclosed.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
ABP-450	Phase 2	Cervical Dystonia

Price & technical context

3-month

-2.6%

6-month

-14.6%

12-month

-98.4%

52-wk range

$0.40–$64.80

vs 50-day MA

-17.1%

vs 200-day MA

+3.3%

Realized vol

222.1%

Max drawdown

-100.0%

Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for AEON (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.